31 January 2017 • Noveome Biotherapeutics, Inc. Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

PITTSBURGH – January 31, 2017 – Noveome Biotherapeutics, Inc., a clinical-stage company and leader in the field of paracrine signaling, today announced the publication of groundbreaking preclinical data in a multiple sclerosis (MS) model with ST266, the company’s novel secretome. Intranasally delivered ST266 demonstrated anti-inflammatory activity and prevented retinal ganglion cell (RGC) loss in the optic nerve, showing its therapeutic potential for treating optic neuritis, the most common presenting sign of MS. The research was conducted in the laboratory of Kenneth S. Shindler, M.D., Ph.D., a professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania, with funding support provided by Noveome, and was published today in Nature Scientific Reports in an article titled, “Intranasal Delivery of a Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function in a Mouse Multiple Sclerosis Model.”